



News Release

Suven to Present at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during November 5 - 7, 2015 at Barcelona, Spain

HYDERABAD, INDIA (November 05, 2015) – *Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during November 5-7, 2015 at Barcelona, Spain.*

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges.

The goal of **8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference** is to bring together today's worldwide leaders in the treatment of Alzheimer's disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments.

During CTAD- 2015 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore potential partnering and out licensing of the clinical candidates SUVN-502, SUVN-G3031, SUVN-D4010 and pre-clinical candidate SUVN-911.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.**

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com